 |
Cross linked hyaluronte acid powde
Bouliga
3913900090
Bouliga
230mda
25kg/bottle
| molecular weight: | |
|---|---|
This ultra-high molecular weight (230,000 kDa) cross-linked sodium hyaluronate powder represents cutting-edge innovation in HA-based biomaterials, designed for specialized research and advanced formulation development. Unlike standard injectable fillers (1,000–2,500 kDa), its exceptional molecular weight enables the creation of highly viscous gels with prolonged tissue retention — a key advantage for sustained-release applications . While not yet approved for clinical use, it serves as a versatile raw material for developing next-generation dermal fillers, tissue engineering scaffolds, and drug delivery systems.
At 230,000 kDa, it far exceeds the molecular weight of conventional HA fillers, forming gels with viscosity exceeding 500,000 cP when reconstituted. This high viscosity slows enzymatic degradation, extending in vivo retention to potentially 12–18 months in preclinical models .
Can be tailored with cross-linking agents like BDDE (1,4-butanediol diglycidyl ether) or PEGDA (polyethylene glycol diacrylate) to adjust gel rigidity, porosity, and degradation rate. This customization allows researchers to optimize formulations for specific applications, from deep volumization to scar revision .
Produced via ultra-purification processes, it is free of animal-derived components, endotoxins (<0.1 EU/mg), and protein residues (<0.1%). It meets USP/NF standards for medical-grade HA, ensuring stability during long-term storage and consistent performance in formulations .
Requires dissolution in sterile saline or phosphate-buffered saline (PBS) at concentrations of 10–20 mg/ml. Gentle agitation (not heating) is recommended to avoid molecular shear, with reconstitution time ranging from 2–4 hours depending on concentration .
In research settings, it is used to develop gels for deep tissue augmentation, where prolonged volume retention is critical. It also serves as a carrier for growth factors (e.g., TGF-β, VEGF) in regenerative medicine, protecting bioactives from degradation and enabling controlled release .
Commonly employed in preclinical studies for tissue engineering, particularly in cartilage repair and wound healing models. Its ability to support cell migration and proliferation makes it a valuable tool for studying HA’s role in tissue regeneration .
Is this product FDA-approved?
No, it is currently classified as a research-grade material and not approved for human or veterinary use. Researchers must obtain institutional review board (IRB) approval before conducting studies involving this powder .
Can it be used for facial fillers?
While its properties suggest potential for facial augmentation, no clinical trials have validated its safety or efficacy in humans. Preliminary animal studies show promising retention but require further testing to assess biocompatibility .
How is it stored?
Store in a cool, dry place (2–8°C) away from light and moisture. When stored properly, the powder remains stable for 24 months from the manufacturing date. Reconstituted gels must be used within 24 hours and discarded if contamination is suspected .
| Item | Parameter | Description |
|---|---|---|
| Main Ingredient | Cross-linked Sodium Hyaluronate | Derived from high-purity hyaluronic acid via microbial fermentation |
| Cross-linking Degree | 12%-18% (customizable) | Determines product hardness and duration, adapting to different application scenarios |
| Molecular Weight | 1,000,000-2,000,000 Da | High molecular weight enhances gel elasticity and support |
| Purity | ≥96% | Strict impurity control reduces allergy risks |
| Appearance | Fine white powder | Uniform and delicate, easily dispersible in aqueous solutions |
| pH Value | 6.5-7.5 | Close to human physiological pH, gentle on skin |
| Solubility | Dispersible in deionized water to form a gel-like solution | Transparency ≥95% after dispersion |
This ultra-high molecular weight (230,000 kDa) cross-linked sodium hyaluronate powder represents cutting-edge innovation in HA-based biomaterials, designed for specialized research and advanced formulation development. Unlike standard injectable fillers (1,000–2,500 kDa), its exceptional molecular weight enables the creation of highly viscous gels with prolonged tissue retention — a key advantage for sustained-release applications . While not yet approved for clinical use, it serves as a versatile raw material for developing next-generation dermal fillers, tissue engineering scaffolds, and drug delivery systems.
At 230,000 kDa, it far exceeds the molecular weight of conventional HA fillers, forming gels with viscosity exceeding 500,000 cP when reconstituted. This high viscosity slows enzymatic degradation, extending in vivo retention to potentially 12–18 months in preclinical models .
Can be tailored with cross-linking agents like BDDE (1,4-butanediol diglycidyl ether) or PEGDA (polyethylene glycol diacrylate) to adjust gel rigidity, porosity, and degradation rate. This customization allows researchers to optimize formulations for specific applications, from deep volumization to scar revision .
Produced via ultra-purification processes, it is free of animal-derived components, endotoxins (<0.1 EU/mg), and protein residues (<0.1%). It meets USP/NF standards for medical-grade HA, ensuring stability during long-term storage and consistent performance in formulations .
Requires dissolution in sterile saline or phosphate-buffered saline (PBS) at concentrations of 10–20 mg/ml. Gentle agitation (not heating) is recommended to avoid molecular shear, with reconstitution time ranging from 2–4 hours depending on concentration .
In research settings, it is used to develop gels for deep tissue augmentation, where prolonged volume retention is critical. It also serves as a carrier for growth factors (e.g., TGF-β, VEGF) in regenerative medicine, protecting bioactives from degradation and enabling controlled release .
Commonly employed in preclinical studies for tissue engineering, particularly in cartilage repair and wound healing models. Its ability to support cell migration and proliferation makes it a valuable tool for studying HA’s role in tissue regeneration .
Is this product FDA-approved?
No, it is currently classified as a research-grade material and not approved for human or veterinary use. Researchers must obtain institutional review board (IRB) approval before conducting studies involving this powder .
Can it be used for facial fillers?
While its properties suggest potential for facial augmentation, no clinical trials have validated its safety or efficacy in humans. Preliminary animal studies show promising retention but require further testing to assess biocompatibility .
How is it stored?
Store in a cool, dry place (2–8°C) away from light and moisture. When stored properly, the powder remains stable for 24 months from the manufacturing date. Reconstituted gels must be used within 24 hours and discarded if contamination is suspected .
| Item | Parameter | Description |
|---|---|---|
| Main Ingredient | Cross-linked Sodium Hyaluronate | Derived from high-purity hyaluronic acid via microbial fermentation |
| Cross-linking Degree | 12%-18% (customizable) | Determines product hardness and duration, adapting to different application scenarios |
| Molecular Weight | 1,000,000-2,000,000 Da | High molecular weight enhances gel elasticity and support |
| Purity | ≥96% | Strict impurity control reduces allergy risks |
| Appearance | Fine white powder | Uniform and delicate, easily dispersible in aqueous solutions |
| pH Value | 6.5-7.5 | Close to human physiological pH, gentle on skin |
| Solubility | Dispersible in deionized water to form a gel-like solution | Transparency ≥95% after dispersion |
